These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 22403278

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1773-82. PubMed ID: 26316621
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pathology after eculizumab in dense deposit disease and C3 GN.
    Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D'Agati VD.
    J Am Soc Nephrol; 2012 Jul 07; 23(7):1229-37. PubMed ID: 22677550
    [Abstract] [Full Text] [Related]

  • 7. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G, EAGLE Study Group.
    Am J Kidney Dis; 2019 Aug 07; 74(2):224-238. PubMed ID: 30929851
    [Abstract] [Full Text] [Related]

  • 8. Eculizumab in a patient with dense-deposit disease.
    Daina E, Noris M, Remuzzi G.
    N Engl J Med; 2012 Mar 22; 366(12):1161-3. PubMed ID: 22435382
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treating C3 glomerulopathy with eculizumab.
    Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E.
    BMC Nephrol; 2018 Jan 12; 19(1):7. PubMed ID: 29329521
    [Abstract] [Full Text] [Related]

  • 15. C3 glomerulopathy: A new complement-based entity.
    de Lorenzo A, Tallón S, Hernández-Sevillano B, de Arriba G.
    Rev Clin Esp (Barc); 2014 Jan 12; 214(5):266-74. PubMed ID: 24576419
    [Abstract] [Full Text] [Related]

  • 16. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl.
    Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F.
    J Nephrol; 2014 Aug 12; 27(4):457-60. PubMed ID: 24536001
    [Abstract] [Full Text] [Related]

  • 17. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.
    Diagn Pathol; 2016 Oct 07; 11(1):94. PubMed ID: 27717365
    [Abstract] [Full Text] [Related]

  • 18. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Frémeaux-Bacchi V, Fakhouri F.
    Am J Kidney Dis; 2018 Jul 07; 72(1):84-92. PubMed ID: 29429752
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K, Martola L, Räisänen-Sokolowski A, Meri S.
    Clin Immunol; 2018 Feb 07; 187():104-106. PubMed ID: 29097196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.